Hospital
Agh Laveen LLC
Agh Laveen LLC was paid $109.33M by Medicaid between Jan 2018 and Dec 2024, across 256 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoAGH LAVEEN LLC
LAVEEN, AZ 85339
LAVEEN, AZ 85339
33aNPI1154748416assigned 03/25/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$109.33M
24GClaims1,984,744
24DCodes billed256
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#2 of 78
Median peer was paid$12.21M
This provider vs. median9.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANSON, JANE controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 291,964 | $16.16M | |
| 2019 | 355,791 | $20.60M | |
| 2020 | 288,133 | $17.65M | |
| 2021 | 342,827 | $19.42M | |
| 2022 | 315,282 | $16.76M | |
| 2023 | 222,848 | $10.94M | |
| 2024incomplete | 167,899 | $7.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 132,379 | 124,904 | $33.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 182,403 | 172,526 | $31.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 74,575 | 69,286 | $24.41M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 14,704 | 13,971 | $7.67M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 16,213 | 15,440 | $3.00M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 27,180 | 26,321 | $2.76M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 4,039 | 3,823 | $1.85M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.4% | 1,761 | 1,659 | $1.53M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15,971 | 15,181 | $1.08M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,191 | 4,988 | $911K |
| G0378 | Hospital observation service, per hour | <1% | 6,111 | 2,513 | $273K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,028 | 987 | $243K |
244 more codes
| 72131 | <1% | 1,591 | $206K | |
| 70491 | <1% | 395 | $148K | |
| 70496 | <1% | 295 | $129K | |
| 10060 | <1% | 2,958 | $128K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,399 | $122K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 31,904 | $89K |
| 70486 | <1% | 2,806 | $87K | |
| 47562 | <1% | 15 | $54K | |
| 74174 | <1% | 65 | $36K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 40,812 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 51,228 | $24K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,596 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,283 | $24K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 41,938 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 93,791 | $17K |
| 71250 | <1% | 1,835 | $14K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 15,525 | $13K |
| 96376 | <1% | 9,385 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,230 | $12K |
| 70498 | <1% | 305 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 30,831 | $10K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13,916 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 34,665 | $8K |
| 93976 | <1% | 3,639 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 24,332 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,302 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 35,539 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 20,380 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 85,511 | $6K |
| 12001 | <1% | 3,855 | $5K | |
| J3490 | Unclassified drugs | <1% | 25,539 | $4K |
| 84703 | <1% | 20,249 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13,483 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,335 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,337 | $3K |
| 93971 | <1% | 3,391 | $3K | |
| 73610 | <1% | 7,164 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 32,500 | $3K |
| 12002 | <1% | 1,505 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,195 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,835 | $2K |
| 84484 | <1% | 24,644 | $2K | |
| 81003 | <1% | 61,495 | $2K | |
| 72128 | <1% | 122 | $2K | |
| 96367 | <1% | 2,009 | $2K | |
| 74018 | <1% | 5,008 | $2K | |
| 83880 | <1% | 6,568 | $2K | |
| 73562 | <1% | 6,745 | $2K | |
| 85379 | <1% | 9,364 | $2K | |
| 81025 | <1% | 32,054 | $2K | |
| 73630 | <1% | 8,379 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,057 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 2,340 | $2K |
| 93975 | <1% | 1,878 | $2K | |
| 84702 | <1% | 7,419 | $1K | |
| 12011 | <1% | 2,530 | $1K | |
| 73030 | <1% | 5,049 | $1K | |
| 76801 | <1% | 3,256 | $1K | |
| 73110 | <1% | 4,866 | $1K | |
| 73130 | <1% | 7,363 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 52,259 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 637 | $1K |
| 71100 | <1% | 1,612 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,999 | $989.93 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,587 | $954.09 |
| 87631 | <1% | 1,934 | $934.30 | |
| 93970 | <1% | 409 | $874.63 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 39,994 | $820.39 |
| 87040 | <1% | 10,211 | $727.86 | |
| 73700 | <1% | 193 | $716.37 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 4,407 | $710.19 |
| 74019 | <1% | 1,795 | $693.20 | |
| 73140 | <1% | 2,949 | $691.89 | |
| 85610 | <1% | 7,768 | $626.31 | |
| 83690 | <1% | 13,443 | $621.34 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,562 | $620.72 |
| 29125 | <1% | 2,118 | $613.39 | |
| 87510 | <1% | 3,753 | $604.31 | |
| 87480 | <1% | 3,756 | $604.19 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,817 | $595.10 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,878 | $542.93 |
| 72100 | <1% | 3,395 | $538.19 | |
| 29130 | <1% | 878 | $536.07 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 788 | $528.87 |
| 90715 | <1% | 6,589 | $517.28 | |
| 87070 | <1% | 1,788 | $513.13 | |
| 94664 | <1% | 3,666 | $508.50 | |
| 87660 | <1% | 3,832 | $479.11 | |
| 73080 | <1% | 2,887 | $448.28 | |
| 87420 | <1% | 1,073 | $427.98 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,772 | $423.30 |
| 73590 | <1% | 1,932 | $422.81 | |
| 80306 | <1% | 9,831 | $412.98 | |
| 80051 | <1% | 2,472 | $375.70 | |
| 82150 | <1% | 6,591 | $354.97 | |
| 83605 | <1% | 10,935 | $347.08 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,526 | $327.62 |
| A9270 | Non-covered item or service | <1% | 28,943 | $290.03 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,580 | $273.67 |
| 72040 | <1% | 1,795 | $256.56 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,802 | $236.05 |
| 87186 | <1% | 1,750 | $233.80 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15,279 | $225.41 |
| 73502 | <1% | 1,604 | $224.06 | |
| 83735 | <1% | 5,553 | $211.33 | |
| 82565 | <1% | 5,272 | $153.04 | |
| 82803 | <1% | 3,014 | $146.59 | |
| 82553 | <1% | 1,037 | $145.54 | |
| 81001 | <1% | 16,117 | $142.91 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 6,121 | $132.02 |
| 82947 | <1% | 6,497 | $130.44 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,981 | $124.33 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,623 | $119.20 |
| 87634 | <1% | 2,714 | $118.55 | |
| 84520 | <1% | 5,251 | $116.68 | |
| 81513 | <1% | 200 | $114.10 | |
| 82550 | <1% | 7,137 | $104.76 | |
| 76870 | <1% | 763 | $93.87 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 288 | $92.62 |
| 31500 | <1% | 13 | $85.47 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,631 | $85.04 |
| 73660 | <1% | 633 | $81.70 | |
| 96368 | <1% | 912 | $81.48 | |
| 29515 | <1% | 600 | $81.17 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,170 | $80.96 |
| 82962 | <1% | 5,855 | $74.31 | |
| 86900 | <1% | 2,035 | $70.02 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,361 | $65.43 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 6,653 | $65.12 |
| 87077 | <1% | 2,066 | $60.24 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,753 | $58.01 |
| S0028 | Injection, famotidine, 20 mg | <1% | 603 | $54.00 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,535 | $54.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,041 | $51.31 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,790 | $50.82 |
| 72072 | <1% | 424 | $49.37 | |
| 87428 | <1% | 518 | $42.00 | |
| 80076 | <1% | 1,972 | $41.16 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 969 | $41.10 |
| 73564 | <1% | 86 | $39.73 | |
| 74021 | <1% | 1,017 | $37.40 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,595 | $36.02 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,124 | $33.83 |
| 86308 | <1% | 742 | $32.72 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,410 | $32.46 |
| 87481 | <1% | 204 | $31.19 | |
| 73090 | <1% | 1,878 | $29.81 | |
| 86901 | <1% | 2,760 | $25.30 | |
| 70360 | <1% | 82 | $24.82 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,814 | $21.26 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,115 | $20.75 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,301 | $19.66 |
| 85027 | <1% | 3,326 | $14.05 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,614 | $12.84 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 950 | $11.47 |
| 80047 | <1% | 247 | $10.90 | |
| 84295 | <1% | 2,774 | $8.32 | |
| 84132 | <1% | 2,901 | $8.20 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,046 | $8.06 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,762 | $7.86 |
| 82435 | <1% | 2,764 | $7.61 | |
| 84100 | <1% | 1,127 | $6.50 | |
| 82374 | <1% | 2,761 | $6.24 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,313 | $5.67 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,568 | $5.40 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 239 | $4.87 |
| 86140 | <1% | 459 | $4.60 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 508 | $4.11 |
| 85007 | <1% | 2,282 | $2.71 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,579 | $1.04 |
| 29530 | 0% | 752 | $0.00 | |
| 87400 | 0% | 21 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 15 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 176 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 82 | $0.00 |
| J1980 | Injection, hyoscyamine sulfate, up to 0.25 mg | 0% | 393 | $0.00 |
| 51702 | 0% | 147 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 166 | $0.00 |
| 69209 | 0% | 107 | $0.00 | |
| 72070 | 0% | 204 | $0.00 | |
| 82272 | 0% | 126 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 216 | $0.00 |
| 29105 | 0% | 393 | $0.00 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 0% | 17 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 110 | $0.00 |
| 87149 | 0% | 26 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| 84439 | 0% | 12 | $0.00 | |
| 51701 | 0% | 12 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 27 | $0.00 |
| 86922 | 0% | 34 | $0.00 | |
| 76770 | 0% | 26 | $0.00 | |
| 36600 | 0% | 29 | $0.00 | |
| 73100 | 0% | 14 | $0.00 | |
| 76802 | 0% | 13 | $0.00 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 16 | $0.00 |
| 16020 | 0% | 12 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| 69200 | 0% | 12 | $0.00 | |
| 72220 | 0% | 12 | $0.00 | |
| 70487 | 0% | 12 | $0.00 | |
| 80329 | 0% | 1,859 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 1,464 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 80 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 545 | $0.00 |
| 85730 | 0% | 1,026 | $0.00 | |
| 85652 | 0% | 382 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 2,004 | $0.00 |
| 71101 | 0% | 356 | $0.00 | |
| 74022 | 0% | 263 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 89 | $0.00 |
| 88304 | 0% | 191 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 1,271 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 112 | $0.00 |
| 80320 | 0% | 2,219 | $0.00 | |
| 94010 | 0% | 81 | $0.00 | |
| 64400 | 0% | 25 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 156 | $0.00 |
| 73060 | 0% | 230 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 480 | $0.00 |
| 73552 | 0% | 268 | $0.00 | |
| 86885 | 0% | 121 | $0.00 | |
| 94760 | 0% | 274 | $0.00 | |
| 94644 | 0% | 32 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 12 | $0.00 |
| 71020 | 0% | 21 | $0.00 | |
| 87147 | 0% | 80 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 226 | $0.00 |
| 72170 | 0% | 93 | $0.00 | |
| 86850 | 0% | 82 | $0.00 | |
| J3030 | Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 0% | 91 | $0.00 |
| 73620 | 0% | 57 | $0.00 | |
| 99406 | 0% | 51 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 44 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 181 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 19 | $0.00 |
| 87205 | 0% | 14 | $0.00 | |
| 93979 | 0% | 19 | $0.00 | |
| 87081 | 0% | 28 | $0.00 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 0% | 49 | $0.00 |
| 11730 | 0% | 44 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 25 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 12 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 61 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSON, JANE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Agh Mesa LLC | Mesa, AZ | $28.01M |
| Agh Laveen LLC | Glendale, AZ | $14.88M |
| Agh Mesa LLC | Mesa, AZ | $4.69M |
| Agh Laveen LLC | Goodyear, AZ | $4.04M |
| Agh Laveen LLC | Surprise, AZ | $3.48M |
| Agh Laveen LLC | Glendale, AZ | $3.40M |
| Agh Mesa LLC | Tempe, AZ | $3.34M |
| Agh Mesa LLC | Chandler, AZ | $2.76M |
| Agh Mesa LLC | Mesa, AZ | $2.66M |
| Agh Mesa LLC | San Tan Valley, AZ | $2.32M |
| Agh Mesa LLC | Phoenix, AZ | $1.74M |
| Agh Mesa LLC | Chandler, AZ | $1.12M |
| Agh Mesa LLC | Gilbert, AZ | $978K |
| Agh Laveen LLC | Mesa, AZ | $293K |
| Agh Laveen LLC | Chandler, AZ | $259K |
| Agh Laveen LLC | Phoenix, AZ | $184K |
| Agh Laveen LLC | Mesa, AZ | $167K |
| Agh Laveen LLC | Gilbert, AZ | $160K |
| Agh Laveen LLC | Chandler, AZ | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.